Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. Financials
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
Delayed Quote. Delayed Nasdaq - 01/25 04:00:00 pm
18.38 USD   +0.88%
01/21Health Care Stocks Retreat This Afternoon
MT
01/21Health Care Stocks Drifting Lower in Friday Trade
MT
01/21CureVac Shares Drop After BofA Securities Downgrade
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023
Capitalization1 11 7133 1003 100-
Enterprise Value (EV)2 10 4432 1242 4352 255
P/E ratio -67,7x-5,63x-11,7x17,7x
Yield ----
Capitalization / Revenue 240x50,2x44,0x34,6x
EV / Revenue 214x34,4x34,6x25,2x
EV / EBITDA -105x-3,97x-14,0x4,46x
Price to Book 12,3x6,72x96,2x245x
Nbr of stocks (in thousands) 176 460187 050187 050-
Reference price (EUR) 66,416,316,316,3
Announcement Date 04/15/2021---
1 USD in Million
2 EUR in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023
Net sales1 17,448,961,870,489,6
EBITDA1 --99,1-535-174506
Operating profit (EBIT)1 --110-524-307-47,4
Operating Margin --225%-848%-435%-52,9%
Pre-Tax Profit (EBT)1 --130-486-241142
Net income1 --129-521-26991,7
Net margin --264%-843%-382%102%
EPS2 -137-0,98-2,89-1,390,92
Dividend per Share2 -----
Announcement Date 04/29/202004/15/2021---
1 EUR in Million
2 EUR
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4
Net sales1 5,166,0012,212,429,3-
EBITDA ------
Operating profit (EBIT)1 -36,8-46,6-130-159-143-104
Operating Margin -712%-777%-1 066%-1 290%-488%-
Pre-Tax Profit (EBT)1 -36,7--141---78,4
Net income1 -36,8--141---78,4
Net margin -714%--1 156%---
EPS2 -0,24-0,32-0,76---0,42
Dividend per Share ------
Announcement Date 11/30/202004/15/2021----
1 EUR in Million
2 EUR
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt1 -----
Net Cash position1 -1 270976665845
Leverage (Debt / EBITDA) -12,8x1,82x3,82x-1,67x
Free Cash Flow1 -486-646-64,0310
ROE (Net Profit / Equities) --38,6%-102%-154%487%
Shareholders' equity1 -33450917518,8
ROA (Net Profit / Asset) ---39,9%-36,0%13,2%
Assets1 --1 307748697
Book Value Per Share2 -5,382,420,170,07
Cash Flow per Share2 -3,95-1,75-1,500,91
Capex1 -36,3303185137
Capex / Sales -74,3%490%262%153%
Announcement Date 04/29/202004/15/2021---
1 EUR in Million
2 EUR
Key data
Capitalization (USD) 3 503 438 858
Net sales (EUR) 48 900 000
Net sales (USD) 55 265 313
Number of employees 505
Sales / Employee (EUR) 96 832
Sales / Employee (USD) 109 436
Free-Float 44,9%
Free-Float capitalization (USD) 1 574 580 618
Avg. Exchange 20 sessions (EUR) 15 650 434
Avg. Exchange 20 sessions (USD) 17 687 651
Average Daily Capital Traded 0,45%
EPS & Dividend